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Isomerisation to all-trans-retinoic acid (ATRA) is widely accepted as the key mechanism underlying the favourable clinical properties
of 13-cis-retinoic acid (13cisRA). As intracellular metabolism of ATRA by CYP26 may result in clinical resistance to 13cisRA, an
increase in efficacy may be achieved through modulation of this metabolic pathway. We have evaluated the effect of the CYP26
inhibitor R116010 on retinoid metabolism in neuroblastoma cell lines and a xenograft model. In neuroblastoma cells, which showed a
high level of CYP26 induction in response to ATRA, R116010 selectively inhibited ATRA metabolism. In addition, siRNA-mediated
knockdown of CYP26 selectively increased ATRA levels and the expression of retinoid-responsive marker genes was potentiated
by R116010. Treatment of mice bearing SH-SY5Y xenografts with 13cisRA (100mgkg
 1) revealed substantial levels (16%)
of intratumoral ATRA after 6h, despite plasma ATRA levels representing only 1% total retinoids under these conditions.
Co-administration of R116010 with 13cisRA in this mouse model resulted in significant increases in plasma ATRA and 13cisRA
concentrations. Furthermore, R116010 induced significant decreases in levels of 4-oxo metabolites in hepatic tissue after co-
administration with either ATRA or 13cisRA. These data suggest considerable potential for CYP26 inhibitors in the future treatment
of neuroblastoma with 13cisRA.
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Retinoic acid (RA) is an active metabolite of vitamin A, which
plays an important role in cell growth and differentiation, and
reverses malignant growth in vitro and in vivo. Retinoic acid and
various synthetic analogues have proved useful agents in tumour
therapy, particularly in the treatment of neuroblastoma, the
commonest extracranial solid tumour of childhood (Reynolds
et al, 2003). The long-term survival rates for stages 3 and 4
neuroblastoma remain low. In a setting of minimal residual
disease, 13-cis-retinoic acid (13cisRA) improved event-free
survival in advanced stage neuroblastoma patients (Matthay
et al, 1999). Peak drug levels in patients receiving 13cisRA as
high-dose pulse therapy after autologous bone marrow trans-
plantation or non-myeloablative therapy were above the 5mM
concentration effective against neuroblastoma cell lines in vitro
(Villablanca et al, 1995). However, approximately 50% of patients
develop resistance or are unresponsive to treatment. Potential
approaches to improve therapy include the optimisation of
pharmacokinetic properties of agents such as 13cisRA.
Retinoids exert their biological effects via nuclear receptors,
the RA receptors (RARs: a, b, g) and the retinoid X receptors
(RXRs: a, b, g) (Petkovich et al, 1987; Mangelsdorf et al, 1992).
13-cis-Retinoic acid has a much lower affinity for these receptors
compared to its stereoisomers, all-trans-retinoic acid (ATRA)
and 9-cis-retinoic acid (9cisRA), and is less active in trans-
activation assays (Idres et al, 2002). 13cisRA is, however, active
in cultured cells and animal models at high doses (Tsukada
et al, 2000; Ponthan et al, 2001; Veal et al, 2002). Although
it is generally accepted that the effects of 13cisRA are mediated
by isomerisation to the more transcriptionally active all-trans or
9-cis isomers (Armstrong et al, 2005a), this does not account
for all pharmacological effects associated with the use of this
retinoid (Blaner, 2001). In contrast to 13cisRA, unfavou-
rable pharmacokinetic and toxicity profiles of ATRA and 9cisRA
have limited their use in neuroblastoma therapy (Reynolds et al,
2003).
Cytochrome P450-mediated oxidation to 4-oxo-RA, 4-hydroxy-
RA, 18-hydroxy-RA and 5,6-epoxy-RA represents the major route
of retinoid catabolism (Marill et al, 2000, 2002). Three mammalian
RA-inducible P450s have been characterised, termed P450RAIs or
CYP26s (White et al, 1997, 2000). CYP26A1 and B1 exhibit a high
degree of specificity for ATRA, while CYP26C1 also metabolises
9cisRA and is much less sensitive to the inhibitory effects of
ketoconazole than A1 and B1 (Taimi et al, 2004). The induction of
CYP26 in response to RA represents a developmentally important
negative feedback loop controlling RA concentrations within cells,
thereby limiting biological action. CYP26A1 mRNA induction has
been reported in skin, intestinal, liver, APL and neuroblastoma
cells treated with RA (Armstrong et al, 2005b; Ozpolat et al, 2005;
Smith et al, 2006), and CYP26A1 protein is highly expressed in
normal human skin (Heise et al, 2006).
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sIncreased ATRA metabolism after prolonged ATRA treatment,
both in vitro and in vivo, has led to the hypothesis that metabolism
has a major role in the emergence of RA resistance (Muindi et al,
1992). Potentiating ATRA efficacy through inhibition of CYP26 is a
novel approach and has led to the development of RA metabolism
blocking agents (RAMBAs). Non-specific P450 inhibitors such as
liarozole increase ATRA effectiveness in vitro and in vivo (Njar,
2002), but the use of liarozole in cancer patients has been limited
by adverse side effects and only moderate ability to inhibit CYP26
(Njar et al, 2006).
A novel inhibitor of RA metabolism, R116010, enhances the
biological activity of ATRA and exhibits antitumour activity as a
single agent in a mouse mammary carcinoma model (Van Heusden
et al, 2002). We have previously shown that R116010 inhibits
ATRA metabolism in SH-SY5Y neuroblastoma cells and increases
the pharmacological effects of both ATRA and 13cisRA (Armstrong
et al, 2005b). The aim of this study was to measure the effect of
R116010 on RA metabolism in a panel of neuroblastoma cell lines,
which differ in their ability to upregulate CYP26 isoforms in
response to RA, and to evaluate the effects of R116010 on RA
metabolism in a neuroblastoma xenograft model.
MATERIALS AND METHODS
Chemicals
The RA isomers 13cisRA and ATRA were from Sigma (Poole, UK).
13-cis-4-oxo-RA (Ro 22-6595), all-trans-4-oxo-RA and acitretin
(Ro 10-1670) were gifts from Hoffmann-La Roche. HPLC-grade
solvents were from Fisher Scientific (Loughborough, UK). R116010
was kindly donated by Barrier Therapeutics Inc. (Princeton, NJ,
USA).
Cell lines
SH-SY5Y, SH-EP (N- and S-type cells respectively derived from the
parental line SK-N-SH), LAN6, IMR-32, NGP and GIMEN
neuroblastoma cell lines were cultured routinely in RPMI 1640
medium containing fetal calf serum (10%) and L-glutamine (2mM).
Cells were grown at 371C in a humidified incubator containing 5%
CO2.
Mice
All in vivo experiments were approved by the relevant institutional
animal welfare committees, and performed according to national
law. Female athymic nude mice (CD-1 nu/nu, Charles River) used
for antitumour studies were maintained and handled in isolators,
under specific pathogen-free conditions, at 241C with a 12h light,
12h dark cycle. Tumours were generated by implantation of
SH-SY5Y cells subcutaneously (s.c.) into one flank of CD-1 nude
mice (1 10
7cells per animal).
Xenografting
Treatments began when the tumours were between 7 and 10mm in
length and breadth. Retinoids and R116010 were initially dissolved
in DMSO before 10- or 20-fold dilutions in PBS, respectively.
For pharmacokinetic studies, the animals were dosed with ATRA
or 13cisRA (each 100mgkg
 1) orally for 0.5, 2 and 6h. For
metabolism studies, animals were treated with R116010 orally at
doses of 1.25 or 2.5mgkg
 1 either immediately before the retinoid
being studied, or up to three times (over 1–2 days) before dosing
with the retinoid. At termination of experiments, animals were
bled under terminal anaesthesia then killed by cervical dislocation.
Plasma was immediately removed from the blood by centrifuga-
tion at 1000g for 5min and snap-frozen in liquid nitrogen in
amber Eppendorfs. Tumour and liver samples were removed and
snap-frozen, wrapped in foil, in liquid nitrogen.
Retinoid treatment
13-cis-Retinoic acid and ATRA were dissolved in DMSO and
diluted in cell culture medium to obtain final concentrations of
0.1–10mM. The final concentration of DMSO in all cases was
o0.2%. All experiments were performed in dim light and tubes
containing retinoids were wrapped in aluminium foil.
Extraction of retinoids
Cell pellets obtained from retinoid incubations were re-suspended
in 2ml cell culture medium and disrupted by passing the samples
several times through a syringe and hypodermic needle (25G 1
inches, 0.5mm 25mm; Terumo, Somerset, NJ, USA). Tumour
and liver tissues were re-suspended in PBS and homogenised (T25
homogeniser, IKA Laboratories, Staufen, Germany). Retinoids
were extracted as described previously (Veal et al, 2002;
Armstrong et al, 2005b). Samples were reconstituted in 200ml
mobile phase A (n-hexane:dichloromethane:propan-2-ol,
400:1:0.27) and analysed by normal-phase HPLC as described
previously (Veal et al, 2002). For LC/MS analysis, samples were
reconstituted in 200ml mobile phase A (50% acetonitrile, 50%
(0.2%) acetic acid, vv
 1).
HPLC analysis
Quantification of retinoid levels was carried out by HPLC analysis
using a Waters 2690 Separations Module and 996 Photodiode
array detector (Waters Ltd, Elstree, UK) and Waters Millennium
software for data acquisition. Cell volumes were determined as
described previously (Veal et al, 2002), and intracellular RA
concentrations were expressed in micromolars.
LC/MS analysis
Resolution of retinoids was performed with a Luna C18(2) column
(3mm, 50mm 2mm) using a Perkin Elmer LC (Beaconsfield, UK)
system, consisting of a vacuum degasser, two series 200 pumps,
a thermostatically controlled series 200 autosampler and a Waters
2487 UV absorbance detector. Retinoic isomers and metabolites
were separated by gradient reversed-phase chromatography. An
injection volume of 20ml with a flow rate of 0.2mlmin
 1 was used
with mobile phase A (50% acetonitrile, 50% (0.2%) acetic acid,
vv
 1) and mobile phase B (acetonitrile, 0.1% acetic acid, vv
 1).
Linear gradients were employed between the specified times as
follows: 0, 100% A; 5min, 100% A; 15min, 100% B; 20min, 100%
B; 23min, 100% A; 35min, 100% A. An Applied Biosystems
(Warrington, UK) API-2000 LC/MS/MS triple Q (quadrupole)
mass spectrometer with electrospray ionisation source, controlled
by Analyst software, was operated in single quadrupole negative
mode for the detection of compounds.
RNA interference of CYP26A1 and B1
CYP26 short hairpin RNAs (shRNAs) were generated using the
siSTRIKE U6 Hairpin Cloning System (Promega, Southampton,
UK). The CYP26A1, B1 and Ctrl siRNA sequences were designed
using Promega software. The cDNA target sequences were
CYP26A1 50-gcgcatcgagcagaacatt; CYP26B1 50-gtcgcggagggagaagtat;
and Ctrl 50-gccccgcaattgagaaatg. Sense and antisense strands were
annealed and ligated into the linearised psiSTRIKE Neomycin
Vector. SH-SY5Y cells were transfected with psi-CYP26A1 or psi-
CYP26B1 either singly or in combination, or with psi-Ctrl, in six-
well plates (1mg each) or 75cm
2 flasks (8.9mg each) using FuGENE
6 reagent (Roche, Lewes, UK) according to the manufacturer’s
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sinstructions. After a 6h transfection, cells were treated with ATRA
for 40h and harvested for RNA isolation and HPLC analysis.
Real-time PCR
RNA was reverse-transcribed using Promega’s Reverse Transcrip-
tion System according to the manufacturer’s instructions, using
random hexamer primers. Real-time PCR was performed on 20ng
cDNA using TaqMan gene expression products for human
CYP26A1, CYP26B1, CRABPII, RARb and MYCN in combination
with the TaqMan Universal PCR master mix (Applied Biosystems,
Warrington, UK). Appropriate controls for non-specific amplifica-
tion and contamination were included. A GeneAmp 5700 Sequence
Detection System was used for real-time PCR amplification. As
internal standard, b-actin was measured simultaneously using the
endogenous control assay provided by Applied Biosystems. PCR
amplification procedures followed manufacturer instructions.
Briefly, the thermocycling program consisted of one cycle at
501C for 2min followed by 951C for 10min and 40 cycles at 951C
(15s) and 601C (1min). Standard curves were generated from
serial dilutions of cDNA prepared from cells treated with ATRA
(1mM) and the data were analysed using the GeneAmp Sequence
Detection System software. CYP26C1 expression was analysed as
described previously (Taimi et al, 2004).
Statistical analysis
Analysis was performed on log-transformed data. General linear
models (GLMs) and analysis of variance (ANOVA) were used to
compare the effects of R116010 on retinoid concentrations in cell
lines and tissues. Since dose (retinoid or R116010) is a quantitative
factor, we have used linear contrasts in the GLM or ANOVA
models (where the sum of contrast coefficients¼0) to test for dose
dependency between treatment and effect. Dunnett’s test was used
to compare treatment with control means. Degrees of freedom in
statistical tests are given as subscripts to the test statistic.
Statistical analyses were carried out using Systat, version 10 (SPSS
Inc., Chicago, IL, USA) and SPSS release 11.0 (SPSS Inc.).
RESULTS
CYP26 isoform induction in neuroblastoma cell lines
Since CYP26 isoforms were not detectable in cells in the absence of
RA, the level of CYP26 induction in each cell line was assessed
relative to CYP26 expression in SH-SY5Y cells treated with 0.01mM
ATRA for 24h. After incubation with 0.1mM ATRA (Figure 1A)
CYP26A1 was induced to various extents in SH-SY5Y, LAN6 and
NGP cells, while CYP26B1 was induced in all cell lines examined,
except IMR-32. Incubation with 0.1mM 13cisRA (Figure 1B)
produced a similar expression pattern, although the magnitude
of response was lower compared to ATRA. CYP26C1 expression
was not detected (by reverse transcription PCR) in any of the cell
lines examined. These results show that CYP26A1 and B1
expression are very sensitive markers of retinoid response in
neuroblastoma cell lines.
R116010 increases retinoid response in neuroblastoma
To assess the effect of R116010 on retinoid response we analysed
the expression of CYP26B1 and other retinoid responsive genes.
CYP26B1, cellular RA-binding protein II (CRABP II), and RARb
expression were analysed in the retinoid-responsive SH-SY5Y cell
line and MYCN expression analysed in the MYCN-amplified NGP
cell line. Figure 2A shows that incubation of SH-SY5Y cells with
R116010 alone (1mM) had no effect on CYP26B1 expression, but
R116010 co-incubated with either ATRA or 13cisRA (0.01, 0.1mM)
significantly increased CYP26B1 expression compared to ATRA or
13cisRA alone. There were also significant increases in both
CRABP II and RARb expression when SH-SY5Y cells were
incubated with ATRA (0.01mM) or 13cisRA (0.1mM) in the presence
of R116010 (1mM) compared to either retinoid alone (Figure 2B
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Figure 1 CYP26 induction in a panel of neuroblastoma cell lines. Reverse-transcribed RNA from neuroblastoma cells treated with 0.1mM ATRA (A)o r
13cisRA (B) for 24h was subjected to real-time PCR using TaqMan probes for CYP26A1, CYP26B1 and b-actin. Values are normalised for b-actin levels and
expressed as fold increase relative to expression of CYP26 in SH-SY5Y cells treated with 0.01mM ATRA. Data are mean values7s.e.m. (nX3).
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sand C). R116010 alone resulted in a small but significant increase
in MYCN expression in the MYCN-amplified NGP cell line.
However, the downregulation of MYCN expression by ATRA or
13cisRA (0.1mM) was enhanced in the presence of R116010 (1mM)
compared to either retinoid alone (Figure 2D). The magnitude of
these responses was greatest with CYP26B1, demonstrating that
CYP26 is a more responsive marker.
Effect of R116010 on intracellular retinoid concentrations
We have previously suggested that R116010 can selectively inhibit
ATRA metabolism in SH-SY5Y cells (Armstrong et al, 2005b). To
test this hypothesis and investigate the effects on 13cisRA levels,
the effect of R116010 was assessed in a panel of cell lines, which
showed differing degrees of CYP26 isoform induction after RA
treatment: two lines showed high levels of CYP26 induction
(SH-SY5Y and NGP) and two showed low or undetectable CYP26
induction (SH-EP and GIMEN). After treatment of these cell lines
with ATRA or 13cisRA alone (10mM) or in combination with
R116010 (1 or 10mM) for 24h there was a difference in relative
levels of isomerisation between the ATRA and 13cisRA treatments,
with ATRA accounting for approximately 15–31% of the total RA
after 13cisRA incubation, compared to 13cisRA accounting for
o10% of total RA after incubation with ATRA (Figure 3). For
analysis, GLMs were used to compare RA isomer concentrations
(ATRA and 13cisRA) with R116010 dose and cell type as fixed
effects. Linear contrasts on R116010 dose were used to verify log
dose-dependent effects, either on individual cell lines or the high/
low CYP26 groups (where there were no significant difference
between cell lines within the group) and incorporating zero dose
as 1 log below the 1mM R116010 concentration. Incubation with
R116010 resulted in significant increases in intracellular ATRA
concentrations after treatment with ATRA in both SH-SY5Y and
NGP cells (linear contrasts: F1,26¼30.26, Po0.00001), but there
was no effect of R116010 on ATRA concentrations in SH-EP or
GIMEN cells (F1,21¼0.017, Po0.9). Conversely, there was no effect
of R116010 on 13cisRA levels after incubation with ATRA for
any of the cell lines (F2,55¼1.24, P¼0.3). With respect to
incubation with 13cisRA, SH-SY5Y cells exhibited a significant
increase in ATRA concentrations after treatment in combination
with R116010 (linear contrast, SH-SY5Y cells: F1,15¼76.07,
Po0.00001) and there was a similar, although nonsignificant,
trend in NGP cells (linear contrast: F1,12¼3.19, P¼0.1). However,
there was no observable effect of R116010 on ATRA levels after
incubation with 13cisRA in SH-EP or GIMEN cells (low CYP26
group, F2,28¼0.29, P40.7). The effect of R116010 was again
specific to ATRA levels, as there were no significant changes in
13cisRA concentrations after incubation with R116010 (GLM,
effect of R116010, F2,57¼0.256, P40.7). Clearly, the activity of
R116010 was limited to increasing the intracellular concentrations
of ATRA only in the cell lines in which CYP26 was inducible to a
high level.
To analyse the effect of R116010 on RA metabolism, LC/MS was
used to evaluate levels of retinoid metabolites in these cells. For the
high CYP26 expressing cells incubated with 10mM ATRA, there
were significant reductions in intracellular AT-4-oxo-RA levels
when co-incubated with R116010 (two-way ANOVA, effect of
R116010: F1,17¼18.9, P¼0.00043; Figure 4) ranging from 3- to 3.8-
fold for SH-SY5Y and NGP cells, respectively. Conversely, for the
low CYP26-expressing cell lines incubated with 10mM ATRA there
was no significant effect of R116010 (F1,13¼0.68, P40.4). R116010
also decreased AT-4-oxo-RA levels 3.5-fold in SH-SY5Y and
13.2-fold in NGP cells incubated with 13cisRA (F1,18¼32.15,
P¼0.000022). Again, there was no significant effect in SH-EP and
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Figure 2 Effect of R116010 on retinoid response. SH-SY5Y cells were incubated with ATRA or 13cisRA (0.01 or 0.1mM) for 24h in the absence or
presence of R116010 (R, 1mM). Reverse-transcribed RNA from SH-SY5Y (A–C) or NGP (D) cells was subjected to real-time PCR using TaqMan probes
for CRABPII, RARb, CYP26 B1, MYCN and b-actin. Values are normalised for b-actin levels and expressed as fold increase relative to gene expression in
control untreated cells (B–D), or to CYP26B1 expression in SH-SY5Y cells treated with 0.01mM ATRA (A). Data are mean values7s.e.m. (nX3). Statistical
significance of gene expression in cells treated with RA in the presence of R116010 relative to those treated with RA alone is indicated by *Po0.05,
***Po0.001.
Inhibition of retinoid metabolism in neuroblastoma
JL Armstrong et al
1678
British Journal of Cancer (2007) 96(11), 1675–1683 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sGIMEN cells (F1,13¼0.02, P40.8) under similar conditions
(Figure 4).
Effect of CYP26A1 and B1 siRNA on ATRA metabolism
To investigate the relationship between CYP26 and ATRA
metabolism, RNA interference experiments were performed in
SH-SY5Y cells to downregulate CYP26A1 and B1. SiRNA to
CYP26A1 inhibited ATRA-induced (0.1mM) CYP26A1 mRNA
expression by approximately 56%, while siRNA to CYP26B1
inhibited ATRA-induced CYP26B1 mRNA expression by approxi-
mately 43% (Figure 5A). These effects were specific for each CYP26
isoform, as siRNA to CYP26A1 did not significantly inhibit
CYP26B1 mRNA expression, and vice versa. Transfection of
CYP26A1 and B1 siRNA together resulted in comparable down-
regulation of each isoform relative to the individual siRNAs,
with approximately 37 and 54% inhibition of CYP26 A1 and B1,
respectively. The corresponding analysis of CYP26 protein
expression was not possible due to a lack of suitable isoform-
specific commercially available antibodies.
The effect of CYP26 siRNA on intracellular ATRA concentra-
tions after ATRA treatment (10mM, 40h) is shown in Figure 5B.
ATRA concentrations increased by 1.5-fold (relative to untreated
controls, not significant) in cells transfected with CYP26A1 siRNA,
by 1.9-fold (P¼0.016) in cells transfected with CYP26B1 siRNA,
and by 2.2-fold (P¼0.023) in cells transfected with both CYP26A1
and B1 siRNA. There were no significant increases in 13cisRA
concentrations under these conditions. These data indicate that
CYP26B1, and to a lesser extent CYP26A1, contribute to ATRA
metabolism in neuroblastoma cells.
Pharmacokinetic analysis of RA in an SH-SY5Y xenograft
model
To determine the effect of R116010 on RA metabolism in vivo,w e
first analysed retinoid concentrations after treatment of CD-1 mice
bearing SH-SY5Y xenografts with either ATRA or 13cisRA at
100mgkg
 1 for 0.5, 2 or 6h (Table 1). Peak plasma levels were
achieved after 2h, and declined over the next 4h, with increasing
concentrations of the equivalent 4-oxo-RA metabolite. 13cisRA
and 13cis-4-oxo-RA, or ATRA and AT-4-oxo-RA, accounted for
o10% of total retinoids at all time points measured after treatment
with ATRA or 13cisRA, respectively. Intratumoral concentrations
of RA isomers and metabolites closely reflected those in plasma
after treatment with ATRA, with ATRA accounting for X80% of
total retinoids at all time points. In comparison, after treatment
with 13cisRA, intratumoral levels of 13cisRA decreased from 90 to
49% of total retinoids over 6h, while intratumoral levels of ATRA,
13cis-4-oxo-RA and AT-4-oxo-RA increased to comparable levels
at 6h.
There was a significant shift from parent drug to the
corresponding 4-oxo metabolite in liver samples after ATRA or
13cisRA treatment. Peak AT-4-oxo-RA levels (2.39mgg
 1)a t6 h
post-ATRA treatment accounted for 45% of total retinoids. An
even greater extent of metabolism was observed after treatment
with 13cisRA, with the peak 13cis-4-oxo-RA concentration
(3.79mgg
 1) accounting for 69% of total retinoids after 6h.
These data indicate that substantial metabolism of ATRA or
13cisRA occurred after 2h, and as such, subsequent combination
treatments with R116010 were performed for 6h to evaluate its
effect on RA metabolism.
Effect of R116010 on retinoid concentrations in an
SH-SY5Y xenograft model
Treatment of mice-bearing SH-SY5Y xenografts with increasing
doses of R116010 in combination with 13cisRA resulted in
significant increases in both 13cisRA and ATRA plasma concen-
trations compared to control animals treated with retinoid alone
(ANOVA F4,15¼13.91, P¼0.00006 and F4,15¼59.3, Po0.00001,
respectively; Figure 6Ai). This effect was dependent on the dose of
R116010 (linear contrasts F1,15¼17.99, P¼0.0007 and F1,13¼22.5,
P¼0.0004), with up to a 4.6-fold increase in 13cisRA plasma
concentration, compared to treatment with 13cisRA alone,
after pretreatment with four doses of R116010 at 2.5mgkg
 1
(Figure 6Ai). There were also small but significant variations in the
plasma concentrations of 13cis-4-oxo-RA and AT-4-oxo-RA after
treatment with 13cisRA in combination with increasing doses of
R116010 at 2.5mgkg
 1 compared to 13cisRA alone (ANOVA
F4,15¼7.15, P¼0.002 and F4,15¼3.71, P¼0.027, respectively).
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Figure 3 Effect of R116010 on ATRA metabolism in neuroblastoma
cells. SH-SY5Y, NGP, SH-EP and GIMEN cells were treated with 10mM
ATRA or 13cisRA in the absence or presence of 1 or 10mM R116010 for
24h. Intracellular ATRA and 13cisRA levels were analysed by normal-phase
HPLC. Values are expressed as concentrations based on cell counts and
cell volume calculations, and data are mean values7s.e.m. (nX4).
Inhibition of retinoid metabolism in neuroblastoma
JL Armstrong et al
1679
British Journal of Cancer (2007) 96(11), 1675–1683 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sHowever, for these metabolites there was either no significant
dose-dependent effect (13cis-4-oxo-RA, linear contrast,
F1,15¼1.25, P¼0.28), or the effect was an apparent linear increase
in metabolite rather than the predicted decrease (linear contrast,
AT-4-oxo-RA, F1,15¼5.85, P¼0.029). Similar although less
marked results were obtained with respect to ATRA plasma
concentrations in ATRA-treated mice, with a maximum 2.3-fold
increase in plasma ATRA concentrations after pretreatment
with four doses of R116010 at 2.5mgkg
 1 (ANOVA F4,14¼3.43,
P¼0.037, linear contrast F1,14¼11.0, P¼0.0051; Figure 6Aii). The
effect on plasma 13cisRA concentrations was marginal (ANOVA,
F4,14¼3.09, P¼0.051). In these experiments, plasma 13cis-4-oxo-
RA was not detectable and there was no effect on plasma AT-4-
oxo-RA levels (ANOVA, F1,14¼0.05, P40.9).
Treatment of mice bearing SH-SY5Y xenografts with R116010 in
combination with 13cisRA resulted in only a marginal apparent
effect on tumour 13cisRA levels compared to 13cisRA alone
(ANOVA F3,10¼3.42, P¼0.06) with only the single dose treatment
with R116010 at 2.5mgkg
 1 producing a significant increase in
tumour 13cisRA levels compared to control animals (0.2270.04
to 0.5970.07mgg
 1, Dunnett’s test P¼0.046). Levels of ATRA in
tumour samples from 13cisRA-treated mice were also not
significantly affected by R116010 treatment (F3,10¼0.69,
P¼0.58). However, CYP26A1 expression in tumours from animals
treated with 13cisRA in combination with two doses of R116010
at 2.5mgkg
 1 increased 4- to 20-fold in individual animals,
compared to CYP26A1 expression after treatment with 13cisRA
alone (data not shown). There were no significant differences in
levels of retinoids measured in tumour tissue after treatment of
animals with R116010 before ATRA and no significant differences
in levels of the 4-oxo-RA metabolites after treatment with either
13cisRA or ATRA, in combination with R116010 compared to
13cisRA or ATRA alone (ANOVA, F3,10o1.02, P40.4). Further-
more, CYP26A1 expression was not significantly different in
tumours from animals treated with R116010 prior ATRA.
In contrast to the results for tumour tissue, treatment of mice
with R116010 before 13cisRA had a marked dose-dependent effect
on concentrations of 13cis-4-oxo-RA and AT-4-oxo-RA in the liver
(ANOVA, F4,15415.18, Po0.0004, linear contrasts F1,15450.28,
A
A
l
l
-
t
r
a
n
s
-
4
-
o
x
o
-
R
A
n
g
/
1
0
6
 
c
e
l
l
s
3.0
2.5
2.0
1.5
1.0
0.5
0.0
B
A
l
l
-
t
r
a
n
s
-
4
-
o
x
o
-
R
A
n
g
/
1
0
6
 
c
e
l
l
s
1.0
0.8
0.6
0.4
0.2
0.0
ctrl
ATRA 13cisRA
R116 ctrl R116
C
A
l
l
-
t
r
a
n
s
-
4
-
o
x
o
-
R
A
n
g
/
1
0
6
 
c
e
l
l
s
0.6
0.4
0.2
0.0
ctrl
ATRA 13cisRA
R116 ctrl R116
ctrl
ATRA 13cisRA
R116 ctrl R116
D
A
l
l
-
t
r
a
n
s
-
4
-
o
x
o
-
R
A
n
g
/
1
0
6
 
c
e
l
l
s
1.25
1.00
0.75
0.50
0.25
0.00 ctrl
ATRA 13cisRA
R116 ctrl R116
Figure 4 Effect of R116010 on ATRA metabolism in neuroblastoma cells. SH-SY5Y (A), NGP (B), SH-EP (C) and GIMEN (D) cells were treated with
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Figure 5 Effect of siRNA to CYP26 on ATRA metabolism. SH-SY5Y cells
were transfected with psi-CYP26A1 (A1), psi-CYP26B1 (B1) either singly
or in combination (A1þB1), or with psi-Ctrl (ctrl). 6h after transfection,
cells were treated with 0.1mM ATRA (A)o r1 0 mM (B) for 40h. In (A)
reverse-transcribed RNA was subjected to real-time PCR using TaqMan
probes for CYP26A1 (grey bars), CYP26B1 (black bars) and b-actin. Values
are normalised for b-actin levels and expressed as fold increase relative to
expression of CYP26 in SH-SY5Y cells treated with 0.01mM ATRA. Data are
mean values7s.e.m. (n¼3). In (B) intracellular ATRA concentrations were
analysed by normal-phase HPLC. Values are expressed as fold increases in
ATRA concentrations based on cell counts and cell volume calculations.
Data are mean values7s.e.m. (n¼3). Statistical significance relative to
control cells is indicated by *Po0.05, **Po0.01.
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sPo0.00001; Figure 6Bi), giving significantly lower levels of both
13cis-4-oxo-RA and AT-4-oxo-RA under all conditions. These
decreases in metabolite concentrations in hepatic tissue were
not associated with 13cisRA levels being different from control
(no R116010) animals (F4,15¼3.32, P¼0.039, Dunnett’s tests not
significant), although liver ATRA levels were increased slightly,
with one and two doses of 2.5mgkg
 1 R116010 (ANOVA,
F4,13¼5.42, P¼0.009; Dunnett’s test, Pp0.044; linear effect not
significant, P¼0.55). Treatment with ATRA in combination with
R116010, or after R116010 pretreatment, resulted in significant
decreases in levels of both 13cis-4-oxo-RA and AT-4-oxo-RA
(ANOVA, F4,1445.58, Po0.007, linear contrasts F1,14417.9,
Po0.0009; Figure 6Bii). No significant increases in liver 13cisRA
or ATRA levels were observed after treatment of animals with
ATRA in combination with R116010 (ANOVA, F4,14 o1.44,
P40.27).
DISCUSSION
For the treatment of high-risk neuroblastoma, 13cisRA is
administered on an intermittent schedule to minimise metabolism
and maintain therapeutic concentrations. Our understanding of
how RA works at a molecular level suggests that 13cisRA acts as a
pro-drug, generating ATRA, the predominant biologically-active
retinoid, by isomerisation. Strategies to increase activity of the
ATRA isomer are, therefore, becoming increasingly important
(Armstrong et al, 2005a). In this study, we observed a preferential
uptake of ATRA compared to 13cisRA in all four cell lines,
alongside a significant shift in RA isomerisation between 13cisRA
and ATRA, after treatment of cells with 13cisRA compared to
ATRA. R116010 selectively inhibited the metabolism of ATRA,
with the magnitude of the R116010 effect proportional to the level
of CYP26 induction in the cell lines. In addition, co-treatment of
SH-SY5Y or NGP cells with R116010 and either ATRA or 13cisRA,
compared to RA alone, resulted in an increased response in terms
of expression of a panel of well-characterised retinoid responsive
genes, consistent with the increase in intracellular ATRA
concentrations. siRNA-mediated downregulation of CYP26 iso-
form expression in SH-SY5Y cells demonstrated the involvement
of CYP26B1 in ATRA metabolism, although the contribution of
CYP26A1 was less clear. Together, these data suggest that RA-
inducible CYP26 is responsible for ATRA metabolism in
neuroblastoma cells.
Preliminary time course experiments in an SH-SY5Y xenograft
model demonstrated that ATRA or 13cisRA were the principle
retinoids in the plasma and tumour fractions after treatment with
ATRA or 13cisRA respectively. There was significant isomerisa-
tion of 13cisRA to ATRA in tumour samples after 13cisRA
treatment, with ATRA accounting for 16% total retinoids after
6h, despite ATRA accounting for only 1% total plasma retinoids
under these conditions. This is in agreement with previous in
vitro and in vivo data (Conley et al,1 9 9 9 ;V e a let al, 2002),
and may represent either a superior uptake of ATRA compared
to 13cisRA into the tumour, or increased intracellular isomerisa-
tion of 13cisRA to the more thermodynamically stable ATRA
isomer.
The greatest effect of R116010 in vivo was observed when co-
administrated with 13cisRA. This resulted in significant increases
in plasma 13cisRA concentrations compared to treatment with
Table 1 Pharmacokinetic analysis of RA in an SH-SY5Y xenograft model
Tissue RA isomer 0.5h % Total retinoids 2h % Total retinoids 6h % Total retinoids
ATRA
Plasma (mM) 13cisRA 0.6770.55 5 1.5570.33 6 1.5370.66 8
ATRA 13.0710.41 91 24.4471.94 88 12.8374.61 70
13cis-4-oxoRA 0.0370.01 o1 0.0270.01 o1 0.0570.03 o1
AT-4-oxoRA 0.670.4 4 1.770.3 6 4.072.4 22
Liver (mgg
 1)
a 13cisRA 0.4270.3 11 0.4070.08 5 0.2570.06 5
ATRA 3.0771.95 77 6.9271.13 81 2.4070.36 46
13cis-4-oxoRA 0.0670.03 1 0.0970.02 1 0.2270.09 4
AT-4-oxoRA 0.4470.12 11 1.0770.05 13 2.3970.72 45
Tumour (mgg
 1)
a 13cisRA 0.0770.07 2 0.2870.07 3 0.1570.03 3
ATRA 2.5972.28 90 9.4172.23 95 3.7870.59 80
13cis-4-oxoRA 0 0 0 0 0 0
AT-4-oxoRA 0.2170.09 8 0.2470.06 2 0.7970.38 17
13cisRA
Plasma (mM) 13cisRA 14.1974.71 93 19.1173.26 93 4.6970.52 78
ATRA 0.6970.49 5 0.5770.57 3 0.0870.08 1
13cis-4-oxoRA 0.2770.11 2 0.6370.10 3 1.2270.24 20
AT-4-oxoRA 0 0 0.1370.04 o10 0
Liver (mgg
 1)
a 13cisRA 3.7771.05 75 2.3370.11 58 0.9870.12 18
ATRA 0.1270.08 2 0.0570.05 1 0.0270.02 o1
13cis-4-oxoRA 0.8970.22 18 1.3370.08 33 3.7970.99 69
AT-4-oxoRA 0.2670.10 5 0.3070.09 8 0.6770.25 12
Tumour (mgg
 1)
a 13cisRA 2.070.67 90 2.1270.57 81 0.2870.04 49
ATRA 0.1570.09 7 0.3770.16 14 0.0970.02 16
13cis-4-oxoRA 0.0670.02 3 0.0470.0 2 0.1170.05 19
AT-4-oxoRA 0.0270.0 o1 0.0970.04 3 0.0970.02 16
Abbreviations: ATRA, all-trans-retinoic acid; LC/MS, liquid chromatography/mass spectrometry; RA, Retinoic acid. CD-1 nude mice bearing SH-SY5Y tumours were treated with
ATRA or 13cisRA (100mgkg
 1). Animals were killed and samples taken 0.5, 5, or 6h after dosing. Retinoid concentrations were analysed by LC/MS. Data are mean
values7s.e.m. (nX3).
aAssume 1g¼1ml.
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oxo-RA concentrations were seen under these conditions, while
parent 13cisRA levels remained unchanged, indicative of an
appreciably reduced metabolism of 13cisRA. As a consequence
of higher 13cisRA levels, there were also higher levels of ATRA in
the plasma and livers of animals treated with 13cisRA and R116010
compared to 13cisRA alone. Furthermore, the induction of
CYP26A1 mRNA in SH-SY5Y tumours in response to 13cisRA
was potentiated by co-treatment with R116010. However, an effect
on ATRA metabolism was detected only when ATRA was
administered with the highest dose of R116010. These results raise
questions concerning the selectivity of R116010, and imply that the
anticancer activity of R116010 may lie primarily in its effects on
systemic RA metabolism.
There was evidence for considerable hepatic metabolism of
13cisRA compared to ATRA suggesting that these animals have
the ability to catabolise 13cisRA more efficiently than ATRA.
Furthermore, the greatest effect of R116010 was seen on 13cisRA
metabolism. As CYP26 isoforms are specific for ATRA, this
indicates that either CYP26 is not responsible for the R116010-
regulatable activity in these animals, or that murine CYP26 is
selective for 13cisRA. The selectivity of R116010 for CYP26
isoforms was determined by its inhibition profile towards other
P450-mediated reactions in rat microsomes, including those
enzymes known to metabolise 13cisRA (Van Heusden et al,
2002). However, this does not rule out selectivity of R116010
towards murine P450 homologues. The identification of the
murine P450 CYP2C39 as an RA 4-hydroxylase (Andreola et al,
2004) demonstrates the existence of murine-specific P450 enzymes
capable of metabolising RA, which in turn may be selective for
13cisRA and be inhibited by R116010. Whether the murine animal
model is appropriate to study the effects of future compounds
capable of inhibiting ATRA metabolism is clearly an important
issue, which needs to be considered in future studies. The
observation that treatment of NGP cells with R116010 alone
resulted in increased expression of the MYCN oncogene in vitro
highlights the need to study MYCN-amplified cell lines in vivo, and
questions the benefit of R116010 as a single agent in this context.
Nevertheless, the effect of R116010 on plasma retinoid
concentrations demonstrates that RAMBAs can inhibit systemic
RA metabolism in vivo, which is likely to be dependent on hepatic
CYP26 expression. Clinically, systemic inhibition of 13cisRA
metabolism may be beneficial in neuroblastoma patients, provi-
ding a reservoir of 13cisRA for isomerisation to ATRA. This may
be particularly advantageous in patients who have lower drug
exposures, with extensive metabolism of 13cisRA and suboptimal
oral administration both recently reported (Veal et al, 2007). There
is considerable potential for RAMBAs to become part of 13cisRA
treatment in neuroblastoma and this is an attractive target for
future drug development. In this respect, it is essential that the
most appropriate animal models are identified and utilised in
future studies.
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Figure 6 Effect of increasing doses of R116010 on plasma (A) and liver (B) retinoid levels in an SH-SY5Y xenograft model. CD-1 nude mice-bearing
SH-SY5Y tumours were treated with 13cisRA (i) or ATRA (ii) (100mgkg
 1), either without or in combination with R116010 at 1.25mgkg
 1 (1.25), or with
one or more doses of R116010 at 2.5mgkg
 1 (2.5 1, 2.5 2, 2.5 4). Animals were sacrificed and samples taken 6h after dosing with retinoid. Plasma
and liver retinoid concentrations were analysed by LC/MS. Data are mean values7s.e.m. (nX3).
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